Valor (es) del activo neto
Valor (es) del activo neto
Seneca Growth Capital VCT Plc (la "Compañía")
4 de abril de 2024
Valor liquidativo (“NAV”)
The Directors and the Investment Manager of the Company, Seneca Partners Limited (“Seneca”), have reviewed the valuation of the Company’s Ordinary and B share investment portfolios and announce an updated NAV for each of the share classes as at 31 March 2024.
Acciones B
As at 31 March 2024, the unaudited NAV per B share was 63.7p.
This is a decrease of 7.0p from the audited NAV as at 31 December 2023 of 70.7p, predominantly as a result of AIM market volatility. The B share NAV as at 31 March 2024 incorporates changes in the bid prices of the B share pool’s AIM/AQSE quoted investments combined with the impact of income receivable and running costs incurred in the period. There have been no material changes in the valuations of any of the unlisted investments during the period from 31 December 2023 to the date of this announcement.
The unaudited NAV total return per B share (NAV plus cumulative dividends) as at 31 March 2024 was 78.7p.
Acciones ordinarias
Al 31 de marzo de 2024, el valor liquidativo no auditado de una acción ordinaria era de 16.8 peniques por acción.
This is a decrease of 1.7p from the audited NAV as at 31 December 2023 of 18.5p and is principally due to a reduction in the value of the Ordinary share pool’s investment in AIM quoted Scancell Holdings Plc and a decrease in the Ordinary share pool’s investment in AIM quoted Arecor Therapeutics Plc. As at 31 March 2024, shares in Scancell Holdings Plc were valued at 10.0p per share (31 December 2023: 10.5p) and shares in Arecor Therapeutics Plc were valued at 135.0p per share (31 December 2023: 180p). The Directors also reviewed the unquoted investments held in the Ordinary share portfolio and concluded that no changes were required to the carrying value of those investments.
The unaudited NAV total return per Ordinary share (NAV plus cumulative dividends) as at 31 March 2024 was 90.1p.
The change in NAV for both the B Shares and Ordinary Shares represents a decrease of 0.1p per share, respectively, on the unaudited NAVs as at 20 March 2024, announced on 22 March 2024 and which was included in the Supplementary Prospectus published by the Company on 28 March 2024.
A los efectos del cálculo del valor liquidativo por acción no auditado para ambas clases de acciones, las inversiones cotizadas se contabilizan a los precios de oferta de cierre al 31 de marzo de 2024 y las inversiones no cotizadas se contabilizan al valor razonable al 31 de marzo de 2024.
El número de acciones B en circulación a 31 de marzo de 2024 era de 21,780,329 y el número de acciones Ordinarias era de 8,115,376. Por tanto, el número total de derechos de voto de la Sociedad es de 29,895,705.
The B share Offer by the Company remains open for the 2023/24 tax year until midday today, 4 April 2024 and shares will be allotted at the above latest published B share NAV.
Este anuncio contiene información privilegiada según lo estipulado en la versión del Reino Unido del Reglamento sobre abuso de mercado n.º 596/2014, que forma parte de la legislación inglesa en virtud de la Ley europea (de retirada) de 2018, modificada. Tras la publicación de este anuncio a través de un servicio de información reglamentaria, esta información se considera de dominio público.
Para más información, por favor póngase en contacto con:
John Hustler, Seneca Growth Capital VCT Plc en GME@dhr-rgv.com
Richard Manley, Seneca Growth Capital VCT Plc en GME@dhr-rgv.com
Cualquier consulta sobre la oferta de suscripción de acciones B deberá dirigirse a:
Matt Currie en Seneca Partners Limited en 01942 295 981 o en GME@dhr-rgv.com